Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-01-05

AUTHORS

Nishitha Thumallapally, Ahmed Meshref, Mohammed Mousa, Terenig Terjanian

ABSTRACT

BackgroundSolitary plasmacytoma (SP) is a localized neoplastic plasma cell disorder with an annual incidence of less than 450 cases. Given the rarity of this disorder, it is difficult to conduct large-scale population studies. Consequently, very limited information on the disorder is available, making it difficult to estimate the incidence and survival rates. Furthermore, limited information is available on the efficacy of various treatment modalities in relation to primary tumor sites.MethodsThe data for this retrospective study were drawn from the Surveillance, Epidemiology and End Results (SEER) database, which comprises 18 registries; patient demographics, treatment modalities and survival rates were obtained for those diagnosed with SP from 1998 to 2007. Various prognostic factors were analyzed via Kaplan-Meier analysis and log-rank test, with 5-year relative survival rate defined as the primary outcome of interest. Cox regression analysis was employed in the multivariate analysis.ResultsThe SEER search from 1998 to 2007 yielded records for 1691 SP patients. The median age at diagnosis was 63 years. The patient cohort was 62.4% male, 37.6% female, 80% Caucasian, 14.6% African American and 5.4% other races. Additionally, 57.8% had osseous plasmacytoma, and 31.9% had extraosseous involvement. Unspecified plasmacytoma was noted in 10.2% of patients. The most common treatment modalities were radiotherapy (RT) (48.8%), followed by combination surgery with RT (21.2%) and surgery alone (11.6%). Univariate analysis of prognostic factors revealed that the survival outcomes were better for younger male patients who received RT with surgery (p < 0.05). Additionally, patients who received neoadjuvant RT had increased survival rates compared to those receiving adjuvant RT (86% vs 73%, p < 0.05). Furthermore, the analyses revealed that 5-year survival rates for patients with axial plasmacytoma were superior when RT was combined with surgery (p < 0.05). In the multivariate analysis, age <60 years and treatment with either RT or surgery showed superior survival rates. Progression to multiple myeloma (MM) was noted in 551 patients. Age >60 years was associated with a lower 5-year survival in patients who progressed to MM compared to those who were diagnosed initially with MM (15.1 vs 16.6%). Finally, those who received RT and progressed to MM still had a higher chance of survival than those who were diagnosed with MM initially and treated with RT/surgery (21.8% vs 15.9%, p < 0.05).ConclusionsA review of the pertinent literature indicates that we provided the most comprehensive population-based analysis of SP to date. Moreover, our study contributes to the establishment of the optimal SP treatment modality, as RT is the favored option in frontline settings. Consensus is currently lacking regarding the benefits of combined treatment including surgery. Thus, the findings reported here elucidate the role of primary treatment modalities while also demonstrating the quantifiable benefits of combining RT with surgery in relation to different primary tumor sites. While our results are promising, they should be confirmed through further large-scale randomized studies. More... »

PAGES

13

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-016-3015-5

DOI

http://dx.doi.org/10.1186/s12885-016-3015-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1013859773

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28056880


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Plasmacytoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proportional Hazards Models", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "SEER Program", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United States", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Staten Island University Hospital, 475 Seaview Avenue, 10305, Staten Island, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.412833.f", 
          "name": [
            "Department of Medicine, Staten Island University Hospital, 475 Seaview Avenue, 10305, Staten Island, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thumallapally", 
        "givenName": "Nishitha", 
        "id": "sg:person.01065015053.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065015053.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Suez Canal University, Ismailia, Egypt", 
          "id": "http://www.grid.ac/institutes/grid.33003.33", 
          "name": [
            "Department of Medicine, Suez Canal University, Ismailia, Egypt"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Meshref", 
        "givenName": "Ahmed", 
        "id": "sg:person.016672665475.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016672665475.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Suez Canal University, Ismailia, Egypt", 
          "id": "http://www.grid.ac/institutes/grid.33003.33", 
          "name": [
            "Department of Medicine, Suez Canal University, Ismailia, Egypt"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mousa", 
        "givenName": "Mohammed", 
        "id": "sg:person.07376074775.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07376074775.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology/oncology, Staten Island University Hospital, Staten Island, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.412833.f", 
          "name": [
            "Department of Hematology/oncology, Staten Island University Hospital, Staten Island, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Terjanian", 
        "givenName": "Terenig", 
        "id": "sg:person.01253717744.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01253717744.62"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1023/a:1023002322935", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053721516", 
          "https://doi.org/10.1023/a:1023002322935"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1756-8722-2-41", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024010356", 
          "https://doi.org/10.1186/1756-8722-2-41"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11864-002-0015-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017483186", 
          "https://doi.org/10.1007/s11864-002-0015-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2407-6-118", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031315902", 
          "https://doi.org/10.1186/1471-2407-6-118"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-01-05", 
    "datePublishedReg": "2017-01-05", 
    "description": "BackgroundSolitary plasmacytoma (SP) is a localized neoplastic plasma cell disorder with an annual incidence of less than 450 cases. Given the rarity of this disorder, it is difficult to conduct large-scale population studies. Consequently, very limited information on the disorder is available, making it difficult to estimate the incidence and survival rates. Furthermore, limited information is available on the efficacy of various treatment modalities in relation to primary tumor sites.MethodsThe data for this retrospective study were drawn from the Surveillance, Epidemiology and End Results (SEER) database, which comprises 18 registries; patient demographics, treatment modalities and survival rates were obtained for those diagnosed with SP from 1998 to 2007. Various prognostic factors were analyzed via Kaplan-Meier analysis and log-rank test, with 5-year relative survival rate defined as the primary outcome of interest. Cox regression analysis was employed in the multivariate analysis.ResultsThe SEER search from 1998 to 2007 yielded records for 1691 SP patients. The median age at diagnosis was 63 years. The patient cohort was 62.4% male, 37.6% female, 80% Caucasian, 14.6% African American and 5.4% other races. Additionally, 57.8% had osseous plasmacytoma, and 31.9% had extraosseous involvement. Unspecified plasmacytoma was noted in 10.2% of patients. The most common treatment modalities were radiotherapy (RT) (48.8%), followed by combination surgery with RT (21.2%) and surgery alone (11.6%). Univariate analysis of prognostic factors revealed that the survival outcomes were better for younger male patients who received RT with surgery (p\u2009<\u20090.05). Additionally, patients who received neoadjuvant RT had increased survival rates compared to those receiving adjuvant RT (86% vs 73%, p\u2009<\u20090.05). Furthermore, the analyses revealed that 5-year survival rates for patients with axial plasmacytoma were superior when RT was combined with surgery (p\u2009<\u20090.05). In the multivariate analysis, age <60 years and treatment with either RT or surgery showed superior survival rates. Progression to multiple myeloma (MM) was noted in 551 patients. Age >60 years was associated with a lower 5-year survival in patients who progressed to MM compared to those who were diagnosed initially with MM (15.1 vs 16.6%). Finally, those who received RT and progressed to MM still had a higher chance of survival than those who were diagnosed with MM initially and treated with RT/surgery (21.8% vs 15.9%, p\u2009<\u20090.05).ConclusionsA review of the pertinent literature indicates that we provided the most comprehensive population-based analysis of SP to date. Moreover, our study contributes to the establishment of the optimal SP treatment modality, as RT is the favored option in frontline settings. Consensus is currently lacking regarding the benefits of combined treatment including surgery. Thus, the findings reported here elucidate the role of primary treatment modalities while also demonstrating the quantifiable benefits of combining RT with surgery in relation to different primary tumor sites. While our results are promising, they should be confirmed through further large-scale randomized studies.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12885-016-3015-5", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "17"
      }
    ], 
    "keywords": [
      "primary tumor site", 
      "multiple myeloma", 
      "treatment modalities", 
      "population-based analysis", 
      "survival rate", 
      "prognostic factors", 
      "multivariate analysis", 
      "tumor site", 
      "comprehensive population-based analysis", 
      "different primary tumor sites", 
      "neoplastic plasma cell disorder", 
      "End Results (SEER) database", 
      "primary treatment modality", 
      "Kaplan-Meier analysis", 
      "young male patient", 
      "plasma cell disorders", 
      "log-rank test", 
      "common treatment modality", 
      "relative survival rates", 
      "superior survival rates", 
      "osseous plasmacytoma", 
      "extraosseous involvement", 
      "neoadjuvant radiotherapy", 
      "adjuvant radiotherapy", 
      "patient demographics", 
      "primary outcome", 
      "median age", 
      "male patients", 
      "annual incidence", 
      "Results database", 
      "combination surgery", 
      "large-scale population studies", 
      "retrospective study", 
      "survival outcomes", 
      "frontline setting", 
      "patient cohort", 
      "SP patients", 
      "survival trends", 
      "cell disorders", 
      "MethodsThe data", 
      "surgery", 
      "patients", 
      "radiotherapy", 
      "plasmacytoma", 
      "limited information", 
      "population studies", 
      "pertinent literature", 
      "disorders", 
      "modalities", 
      "regression analysis", 
      "higher chance", 
      "age", 
      "African Americans", 
      "incidence", 
      "survival", 
      "outcomes", 
      "treatment", 
      "years", 
      "myeloma", 
      "registry", 
      "cohort", 
      "epidemiology", 
      "study", 
      "diagnosis", 
      "progression", 
      "rate", 
      "Caucasians", 
      "demographics", 
      "efficacy", 
      "ConclusionsA review", 
      "factors", 
      "rarity", 
      "surveillance", 
      "males", 
      "involvement", 
      "benefits", 
      "review", 
      "options", 
      "findings", 
      "setting", 
      "analysis", 
      "Americans", 
      "consensus", 
      "records", 
      "database", 
      "cases", 
      "sites", 
      "race", 
      "role", 
      "chance", 
      "test", 
      "date", 
      "effect", 
      "quantifiable benefits", 
      "search", 
      "information", 
      "literature", 
      "data", 
      "relation", 
      "results", 
      "trends", 
      "establishment", 
      "USA", 
      "sp", 
      "interest"
    ], 
    "name": "Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA", 
    "pagination": "13", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1013859773"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-016-3015-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28056880"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-016-3015-5", 
      "https://app.dimensions.ai/details/publication/pub.1013859773"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:36", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_737.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12885-016-3015-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-016-3015-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-016-3015-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-016-3015-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-016-3015-5'


 

This table displays all metadata directly associated to this object as RDF triples.

255 TRIPLES      21 PREDICATES      146 URIs      134 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-016-3015-5 schema:about N178eda63a5fd48ed8685adfdf1fe61c9
2 N2e7df99e21224965bb27101b4c08c23e
3 N31870e02669340229e17f7b1dd05b3a8
4 N37b0e9dbb67b4a30811d9a387c4b38de
5 N3f423bcb753d4630ad999ee47fd34bde
6 N466bcdec2a364a3ca4dc87af966e6b92
7 N6817d1d305334f139abce4e32bfebe13
8 N84cfce92db4f40978f85f30d7da9129a
9 N873e8ef11a024d9cb60a28816db38808
10 Na7be385167834c04ba62d0058bf5c6e5
11 Ncbeaf10a1dc642cca08c371fe0013c69
12 Ncc81dc2bbdc5465c9e3717889b23e5f3
13 anzsrc-for:11
14 anzsrc-for:1117
15 schema:author N391393a008884385b7dcb71aad33d53f
16 schema:citation sg:pub.10.1007/s11864-002-0015-2
17 sg:pub.10.1023/a:1023002322935
18 sg:pub.10.1186/1471-2407-6-118
19 sg:pub.10.1186/1756-8722-2-41
20 schema:datePublished 2017-01-05
21 schema:datePublishedReg 2017-01-05
22 schema:description BackgroundSolitary plasmacytoma (SP) is a localized neoplastic plasma cell disorder with an annual incidence of less than 450 cases. Given the rarity of this disorder, it is difficult to conduct large-scale population studies. Consequently, very limited information on the disorder is available, making it difficult to estimate the incidence and survival rates. Furthermore, limited information is available on the efficacy of various treatment modalities in relation to primary tumor sites.MethodsThe data for this retrospective study were drawn from the Surveillance, Epidemiology and End Results (SEER) database, which comprises 18 registries; patient demographics, treatment modalities and survival rates were obtained for those diagnosed with SP from 1998 to 2007. Various prognostic factors were analyzed via Kaplan-Meier analysis and log-rank test, with 5-year relative survival rate defined as the primary outcome of interest. Cox regression analysis was employed in the multivariate analysis.ResultsThe SEER search from 1998 to 2007 yielded records for 1691 SP patients. The median age at diagnosis was 63 years. The patient cohort was 62.4% male, 37.6% female, 80% Caucasian, 14.6% African American and 5.4% other races. Additionally, 57.8% had osseous plasmacytoma, and 31.9% had extraosseous involvement. Unspecified plasmacytoma was noted in 10.2% of patients. The most common treatment modalities were radiotherapy (RT) (48.8%), followed by combination surgery with RT (21.2%) and surgery alone (11.6%). Univariate analysis of prognostic factors revealed that the survival outcomes were better for younger male patients who received RT with surgery (p < 0.05). Additionally, patients who received neoadjuvant RT had increased survival rates compared to those receiving adjuvant RT (86% vs 73%, p < 0.05). Furthermore, the analyses revealed that 5-year survival rates for patients with axial plasmacytoma were superior when RT was combined with surgery (p < 0.05). In the multivariate analysis, age <60 years and treatment with either RT or surgery showed superior survival rates. Progression to multiple myeloma (MM) was noted in 551 patients. Age >60 years was associated with a lower 5-year survival in patients who progressed to MM compared to those who were diagnosed initially with MM (15.1 vs 16.6%). Finally, those who received RT and progressed to MM still had a higher chance of survival than those who were diagnosed with MM initially and treated with RT/surgery (21.8% vs 15.9%, p < 0.05).ConclusionsA review of the pertinent literature indicates that we provided the most comprehensive population-based analysis of SP to date. Moreover, our study contributes to the establishment of the optimal SP treatment modality, as RT is the favored option in frontline settings. Consensus is currently lacking regarding the benefits of combined treatment including surgery. Thus, the findings reported here elucidate the role of primary treatment modalities while also demonstrating the quantifiable benefits of combining RT with surgery in relation to different primary tumor sites. While our results are promising, they should be confirmed through further large-scale randomized studies.
23 schema:genre article
24 schema:isAccessibleForFree true
25 schema:isPartOf Na8ff88a593374ab9a37d2dfd35ac1287
26 Nd93d10d156d148b38512e4be2ddc7540
27 sg:journal.1024632
28 schema:keywords African Americans
29 Americans
30 Caucasians
31 ConclusionsA review
32 End Results (SEER) database
33 Kaplan-Meier analysis
34 MethodsThe data
35 Results database
36 SP patients
37 USA
38 adjuvant radiotherapy
39 age
40 analysis
41 annual incidence
42 benefits
43 cases
44 cell disorders
45 chance
46 cohort
47 combination surgery
48 common treatment modality
49 comprehensive population-based analysis
50 consensus
51 data
52 database
53 date
54 demographics
55 diagnosis
56 different primary tumor sites
57 disorders
58 effect
59 efficacy
60 epidemiology
61 establishment
62 extraosseous involvement
63 factors
64 findings
65 frontline setting
66 higher chance
67 incidence
68 information
69 interest
70 involvement
71 large-scale population studies
72 limited information
73 literature
74 log-rank test
75 male patients
76 males
77 median age
78 modalities
79 multiple myeloma
80 multivariate analysis
81 myeloma
82 neoadjuvant radiotherapy
83 neoplastic plasma cell disorder
84 options
85 osseous plasmacytoma
86 outcomes
87 patient cohort
88 patient demographics
89 patients
90 pertinent literature
91 plasma cell disorders
92 plasmacytoma
93 population studies
94 population-based analysis
95 primary outcome
96 primary treatment modality
97 primary tumor site
98 prognostic factors
99 progression
100 quantifiable benefits
101 race
102 radiotherapy
103 rarity
104 rate
105 records
106 registry
107 regression analysis
108 relation
109 relative survival rates
110 results
111 retrospective study
112 review
113 role
114 search
115 setting
116 sites
117 sp
118 study
119 superior survival rates
120 surgery
121 surveillance
122 survival
123 survival outcomes
124 survival rate
125 survival trends
126 test
127 treatment
128 treatment modalities
129 trends
130 tumor site
131 years
132 young male patient
133 schema:name Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA
134 schema:pagination 13
135 schema:productId N1a7d4a8dd4c34413bef8cf646c70325e
136 N358094a0d29c484da28aab6d2f61900c
137 Ne4819ab653804cf4a22569d2363ca4f7
138 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013859773
139 https://doi.org/10.1186/s12885-016-3015-5
140 schema:sdDatePublished 2022-12-01T06:36
141 schema:sdLicense https://scigraph.springernature.com/explorer/license/
142 schema:sdPublisher Neeb585ede5974b6481a4a87ca74a1b5f
143 schema:url https://doi.org/10.1186/s12885-016-3015-5
144 sgo:license sg:explorer/license/
145 sgo:sdDataset articles
146 rdf:type schema:ScholarlyArticle
147 N178eda63a5fd48ed8685adfdf1fe61c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Proportional Hazards Models
149 rdf:type schema:DefinedTerm
150 N1a7d4a8dd4c34413bef8cf646c70325e schema:name dimensions_id
151 schema:value pub.1013859773
152 rdf:type schema:PropertyValue
153 N2e7df99e21224965bb27101b4c08c23e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Kaplan-Meier Estimate
155 rdf:type schema:DefinedTerm
156 N31870e02669340229e17f7b1dd05b3a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name United States
158 rdf:type schema:DefinedTerm
159 N358094a0d29c484da28aab6d2f61900c schema:name pubmed_id
160 schema:value 28056880
161 rdf:type schema:PropertyValue
162 N37b0e9dbb67b4a30811d9a387c4b38de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Retrospective Studies
164 rdf:type schema:DefinedTerm
165 N391393a008884385b7dcb71aad33d53f rdf:first sg:person.01065015053.14
166 rdf:rest Naa35ab86cf734a0a9f2bba2911060469
167 N3f01cdba592d4dcf8bec4801b7851240 rdf:first sg:person.07376074775.06
168 rdf:rest N5f4cf397a37e49a382f6f9ddacb5a4c3
169 N3f423bcb753d4630ad999ee47fd34bde schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Adult
171 rdf:type schema:DefinedTerm
172 N466bcdec2a364a3ca4dc87af966e6b92 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Plasmacytoma
174 rdf:type schema:DefinedTerm
175 N5f4cf397a37e49a382f6f9ddacb5a4c3 rdf:first sg:person.01253717744.62
176 rdf:rest rdf:nil
177 N6817d1d305334f139abce4e32bfebe13 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Aged
179 rdf:type schema:DefinedTerm
180 N84cfce92db4f40978f85f30d7da9129a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Middle Aged
182 rdf:type schema:DefinedTerm
183 N873e8ef11a024d9cb60a28816db38808 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name SEER Program
185 rdf:type schema:DefinedTerm
186 Na7be385167834c04ba62d0058bf5c6e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Male
188 rdf:type schema:DefinedTerm
189 Na8ff88a593374ab9a37d2dfd35ac1287 schema:issueNumber 1
190 rdf:type schema:PublicationIssue
191 Naa35ab86cf734a0a9f2bba2911060469 rdf:first sg:person.016672665475.61
192 rdf:rest N3f01cdba592d4dcf8bec4801b7851240
193 Ncbeaf10a1dc642cca08c371fe0013c69 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Female
195 rdf:type schema:DefinedTerm
196 Ncc81dc2bbdc5465c9e3717889b23e5f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Humans
198 rdf:type schema:DefinedTerm
199 Nd93d10d156d148b38512e4be2ddc7540 schema:volumeNumber 17
200 rdf:type schema:PublicationVolume
201 Ne4819ab653804cf4a22569d2363ca4f7 schema:name doi
202 schema:value 10.1186/s12885-016-3015-5
203 rdf:type schema:PropertyValue
204 Neeb585ede5974b6481a4a87ca74a1b5f schema:name Springer Nature - SN SciGraph project
205 rdf:type schema:Organization
206 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
207 schema:name Medical and Health Sciences
208 rdf:type schema:DefinedTerm
209 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
210 schema:name Public Health and Health Services
211 rdf:type schema:DefinedTerm
212 sg:journal.1024632 schema:issn 1471-2407
213 schema:name BMC Cancer
214 schema:publisher Springer Nature
215 rdf:type schema:Periodical
216 sg:person.01065015053.14 schema:affiliation grid-institutes:grid.412833.f
217 schema:familyName Thumallapally
218 schema:givenName Nishitha
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065015053.14
220 rdf:type schema:Person
221 sg:person.01253717744.62 schema:affiliation grid-institutes:grid.412833.f
222 schema:familyName Terjanian
223 schema:givenName Terenig
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01253717744.62
225 rdf:type schema:Person
226 sg:person.016672665475.61 schema:affiliation grid-institutes:grid.33003.33
227 schema:familyName Meshref
228 schema:givenName Ahmed
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016672665475.61
230 rdf:type schema:Person
231 sg:person.07376074775.06 schema:affiliation grid-institutes:grid.33003.33
232 schema:familyName Mousa
233 schema:givenName Mohammed
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07376074775.06
235 rdf:type schema:Person
236 sg:pub.10.1007/s11864-002-0015-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017483186
237 https://doi.org/10.1007/s11864-002-0015-2
238 rdf:type schema:CreativeWork
239 sg:pub.10.1023/a:1023002322935 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053721516
240 https://doi.org/10.1023/a:1023002322935
241 rdf:type schema:CreativeWork
242 sg:pub.10.1186/1471-2407-6-118 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031315902
243 https://doi.org/10.1186/1471-2407-6-118
244 rdf:type schema:CreativeWork
245 sg:pub.10.1186/1756-8722-2-41 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024010356
246 https://doi.org/10.1186/1756-8722-2-41
247 rdf:type schema:CreativeWork
248 grid-institutes:grid.33003.33 schema:alternateName Department of Medicine, Suez Canal University, Ismailia, Egypt
249 schema:name Department of Medicine, Suez Canal University, Ismailia, Egypt
250 rdf:type schema:Organization
251 grid-institutes:grid.412833.f schema:alternateName Department of Hematology/oncology, Staten Island University Hospital, Staten Island, NY, USA
252 Department of Medicine, Staten Island University Hospital, 475 Seaview Avenue, 10305, Staten Island, NY, USA
253 schema:name Department of Hematology/oncology, Staten Island University Hospital, Staten Island, NY, USA
254 Department of Medicine, Staten Island University Hospital, 475 Seaview Avenue, 10305, Staten Island, NY, USA
255 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...